Potential danger to public health: Italy on misuse of Parvulan as COVID treatment

Published On 2021-09-11 10:42 GMT   |   Update On 2021-09-11 10:42 GMT
Advertisement

Milan: Italy's medicines agency AIFA warned on Friday against the misuse of an unlicensed antiviral drug as a COVID-19 therapy, calling it a potential danger to people's health.

Regulators said the Ministry of Health had alerted them of a high number of requests to import Parvulan, an antiviral drug used as treatment for Herpes Zoster, which is not authorised in Italy but legally registered and marketed in Brazil.

Advertisement

AIFA added that requests from customers in Italy showed that Parvulan is being proposed off-label - for uses different from its original purpose - as a treatment for the prevention of COVID-19, in alternative to licensed vaccines.

"The use of the drug Parvulan in the prophylaxis of Sars-COV-2 infection is not supported by the slightest evidence, under the profile of efficacy and safety", the agency said in a statement, adding its scientific committee had not even authorised it in a clinical trial.

Read also: No efficacy data of Regdanvimab on COVID variants in India: CDSCO panel rejects Abbott proposal

"The possible use of the drug as a substitute for authorised vaccines therefore represents a potential danger to human health", AIFA said.

The danger would not only be due to the lack of safety in its use but also to the unjustified sense of protection patients would have from it, given the lack of documented efficacy, the regulator added in its statement.

Read also: EMA lists nerve disorder as side effect of AstraZeneca COVID vaccine



Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News